Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | APAF1 | O14727 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23133058 | 0.89 | APAF1 (0.46) | ALDH1A1APAF1GAAELANEKDM4E | |
| SCHEMBL16653859 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL29181850 | 0.82 | — | — | |
| SCHEMBL6209985 | 0.80 | — | — | |
| SCHEMBL7861180 | 0.80 | — | — | |
| SCHEMBL11886045 | 0.80 | — | — | |
| SCHEMBL1164275 | 0.76 | IDH1 (0.32) | — | |
| SCHEMBL4601152 | 0.72 | — | — | |
| SCHEMBL29395461 | 0.71 | ATG4B (0.33) | — | |
| SCHEMBL5987355 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10933142-B2 | Reversible covalent linkage of functional molecules | UCL BUSINESS LTD (GB) | 2021-03-02 | — | — | US | disclosed |
| US-10933142-B2 | Reversible covalent linkage of functional molecules | UCL BUSINESS LTD (GB) | 2021-03-02 | — | — | US | disclosed |
| US-20200108150-A1 | REVERSIBLE COVALENT LINKAGE OF FUNCTIONAL MOLECULES | UCL BUSINESS LTD (GB) | 2020-04-09 | — | — | US | disclosed |
| US-10548982-B2 | Reversible covalent linkage of functional molecules | UCL BUSINESS LTD (GB) | 2020-02-04 | — | — | US | disclosed |
| US-10548982-B2 | Reversible covalent linkage of functional molecules | UCL BUSINESS LTD (GB) | 2020-02-04 | — | — | US | disclosed |
| US-20190142950-A1 | Reversible Covalent Linkage of Functional Molecules | UCL BUSINESS LTD (GB) | 2019-05-16 | — | — | US | disclosed |
| US-20190142950-A1 | Reversible Covalent Linkage of Functional Molecules | UCL BUSINESS LTD (GB) | 2019-05-16 | — | — | US | disclosed |
| US-10174094-B2 | Reversible covalent linkage of functional molecules | UCL BUSINESS PLC (GB) | 2019-01-08 | — | — | US | disclosed |
| US-10174094-B2 | Reversible covalent linkage of functional molecules | UCL BUSINESS PLC (GB) | 2019-01-08 | — | — | US | disclosed |
| US-20160176942-A1 | Reversible Covalent Linkage of Functional Molecules | UCL BUSINESS PLC (GB) | 2016-06-23 | — | — | US | disclosed |
| US-20120190579-A1 | Functionalisation of Solid Substrates | UCL BUSINESS PLC (GB) | 2012-07-26 | — | — | US | disclosed |
| US-20120190579-A1 | Functionalisation of Solid Substrates | UCL BUSINESS PLC (GB) | 2012-07-26 | — | — | US | disclosed |
| US-20120190579-A1 | Functionalisation of Solid Substrates | UCL BUSINESS PLC (GB) | 2012-07-26 | — | — | US | disclosed |
| US-20120190124-A1 | Reversible Covalent Linkage of Functional Molecules | UCL BUSINESS LTD (GB) | 2012-07-26 | — | — | US | disclosed |
| EP-2464974-A1 | FUNCTIONALISATION OF SOLID SUBSTRATES | UCL Business PLC (GB) | 2012-06-20 | — | — | EP | disclosed |
| EP-2464972-A1 | REVERSIBLE COVALENT LINKAGE OF FUNCTIONAL MOLECULES | UCL Business PLC (GB) | 2012-06-20 | — | — | EP | disclosed |
| WO-2011018611-A1 | REVERSIBLE COVALENT LINKAGE OF FUNCTIONAL MOLECULES | UCL BUSINESS PLC (GB) | 2011-02-17 | — | — | WO | disclosed |
| WO-2011018613-A1 | FUNCTIONALISATION OF SOLID SUBSTRATES | UCL BUSINESS PLC (GB) | 2011-02-17 | — | — | WO | disclosed |
| WO-2011018613-A1 | FUNCTIONALISATION OF SOLID SUBSTRATES | UCL BUSINESS PLC (GB) | 2011-02-17 | — | — | WO | disclosed |
| WO-2011018611-A1 | REVERSIBLE COVALENT LINKAGE OF FUNCTIONAL MOLECULES | UCL BUSINESS PLC (GB) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174094-B2 | Reversible covalent linkage of functional molecules | F12, F13A1, F2 | LMNA 3420/4885ALDH1A1 76/4885APAF1 2067/4885 |
| US-20120190124-A1 | Reversible Covalent Linkage of Functional Molecules | F12, F13A1, F2 | LMNA 3420/4885ALDH1A1 76/4885APAF1 2067/4885 |
| US-20190142950-A1 | Reversible Covalent Linkage of Functional Molecules | F12, F13A1, F2 | LMNA 3420/4885ALDH1A1 76/4885APAF1 2067/4885 |
| US-20120190579-A1 | Functionalisation of Solid Substrates | XDH, SPR, DAO | LMNA 3016/4885ALDH1A1 3038/4885APAF1 1894/4885 |
| US-20160176942-A1 | Reversible Covalent Linkage of Functional Molecules | F12, F13A1, F2 | LMNA 3420/4885ALDH1A1 76/4885APAF1 2067/4885 |
| US-10548982-B2 | Reversible covalent linkage of functional molecules | F12, F13A1, F2 | LMNA 3420/4885ALDH1A1 76/4885APAF1 2067/4885 |
| US-10933142-B2 | Reversible covalent linkage of functional molecules | F12, F13A1, F2 | LMNA 3420/4885ALDH1A1 76/4885APAF1 2067/4885 |
| US-20200108150-A1 | REVERSIBLE COVALENT LINKAGE OF FUNCTIONAL MOLECULES | F12, F13A1, F2 | LMNA 3309/4885ALDH1A1 80/4885APAF1 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.